Differential Diagnosis Between Classic Hodgkin's Lymphoma, T-Cell-Rich B-Cell Lymphoma, and Paragranuloma by Paraffin Immunohistochemistry

1998 ◽  
Vol 22 (10) ◽  
pp. 1184-1191 ◽  
Author(s):  
Thomas Rüdiger ◽  
German Ott ◽  
Maria Michaela Ott ◽  
Sigrid Maria Müller-Deubert ◽  
Hans Konrad Müller-Hermelink
Keyword(s):  
Differential Diagnosis ◽  
T Cell ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma

scholarly journals Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project

2017 ◽  
Vol 76 (12) ◽  
pp. 2025-2030 ◽  
Author(s):  
Louise K Mercer ◽  
Anne C Regierer ◽  
Xavier Mariette ◽  
William G Dixon ◽  
Eva Baecklund ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
T Cell ◽  
General Population ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Treatment Groups ◽  
Increased Risk

BackgroundLymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes.MethodsPatients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD.ResultsAmong 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population.ConclusionThis large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.

scholarly journals Pattern of Immunophenotype Among the Cases of Lymphoma Attending in A Tertiary Level Hospital

2019 ◽  
Vol 17 (2) ◽  
pp. 21-25
Author(s):  
Shirajam Munira ◽  
Salama Afroze ◽  
Akhil Ranjon Biswas ◽  
MA Khan
Keyword(s):  
T Cell ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
College Hospital ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Background : To explore the relative frequency and different forms of lymphoma in tertiary level hospital. Methods: This descriptive observational study was carried out in the Department of Hematology at Dhaka Medical College Hospital, Dhaka. Patients attended with solid tissue lymphoma in Outpatient, Inpatient and Lymphoma Clinic services of Department of Hematology and Bone Marrow Transplant, Dhaka Medical College Hospital, Dhaka were taken as study population as per inclusion criteria. A total of 63 patients with lymphoma diagnosed by histopathologically were selected initially, among them 53 were confirmed by immunohistochemistry taken as study population finally. Results: Mean age was 39.2 ± 15.5 years, median age was 36 years within the range of 14 – 75 years. Males were predominant. Male female ratio was 4.3:1. Most of the samples were collected from cervical lymph node (84.1%). Most of the patients came with fatigue and significant weight loss. Maximum 42 (79.24%) cases were Non-Hodgkin’s lymphoma and 11 (20.75%) cases were Hodgkin’s lymphoma. Out of 42 non-Hodgkin’s lymphoma, 27 (64.3%) were B-cell lymphoma and 15 (35.7%) were T-cell lymphoma. Among B-cell lymphoma, 19 (45.2%) were diffuse large B cell lymphoma, three (7.1%) were follicular lymphoma, three (7.1%) were mantle cell lymphoma, one (2.4%) was spleenic marginal zone lymphoma and one (2.4%) was Burkitt lymphoma. Among T-cell lymphoma, nine (21.4%) were peripheral T-cell lymphoma and six (14.3%) were adult T lymphoblastic lymphoma. Out of 11 Hodgkin’s lymphoma, 10 (90.9%) were classical Hodgkin’s lymphoma and one (9.1%) nodular lymphocyte predominant. Among classical Hodgkin’s lymphoma, five (45.5%) were mixed cellularity, three (27.3%) were lymphocyte predominant and two (18.2%) were Nodular sclerosis. Out of 42 non-Hodgkin’s lymphoma, 13 (30.95%) were indolent, 21 (50.00%) were aggressive and eight (19.05%) were very aggressive. Conclusion: In our study, it was found that 79.3% were non-Hodgkin lymphoma of which 64.3% were B-cell lymphoma & 35.7% were T-cell lymphoma and 20.7% cases were Hodgkin lymphoma of which 90.9% were classical Hodgkin’s lymphoma, 9.1% nodular lymphocyte predominant Hodgkin’s lymphoma. Chatt Maa Shi Hosp Med Coll J; Vol.17 (2); Jul 2018; Page 21-25

scholarly journals Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte‐rich B cell lymphoma

2002 ◽  
Vol 13 ◽  
pp. 44-51 ◽  
Author(s):  
T. Rüdiger ◽  
R.D. Gascoyne ◽  
E.S. Jaffe ◽  
D. de Jong ◽  
J. Delabie ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
The Relationship

scholarly journals INCREASED RISK OF LYMPHOMA IN MEN INFECTED WITH TUBERCULOSIS

2021 ◽  
Vol 13 (1) ◽  
pp. e2021053
Author(s):  
Guangliang Chen
Keyword(s):  
Mycobacterium Tuberculosis ◽  
T Cell ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Male Gender ◽  
Hodgkin's Lymphoma ◽  
Benign Tumors ◽  
Control Analysis

Purpose: To identify factors associated with lymphoma in patients with anterior Mycobacterium tuberculosis (TB). Methods: A retrospective case-control analysis was performed in a highly tuberculosis-endemic area. TB-infected patients were retrospectively identified when a history of TB exists before the diagnosis of lymphoma. Inpatients with lymphoma (n=1,057) and benign tumors (n=12,916) were consecutively enrolled at Xinjiang Medical University Cancer Hospital between January 2016 and December 2019. Results: The proportion of TB in patients with lymphoma (n=148, 14.0%) was significantly higher than that in the control (benign tumor) group (n=175, 1.4%) (p<0.0001). The frequency of TB infection in patients with Hodgkin’s lymphoma, B-cell non-Hodgkin’s lymphoma (NHL), and T/NK-cell NHL is 13.6%, 14.6%, and 11.9%, respectively. Compared to other subtypes of B-cell NHL, a relatively high proportion of tuberculosis was found in patients with chronic lymphocytic leukemia /small lymphocytic lymphoma, marginal zone B-cell lymphoma, diffuse large B-cell lymphoma, corresponding to 20.6%, 18.6% and 15.3%, respectively. For T-cell NHL, the proportion of TB infection in patients with peripheral T-cell lymphoma and anaplastic lymphoma kinase-positive T-cell NHL was 26.1% and 20%, respectively. Multivariate analysis revealed male gender as an adverse risk factor was associated with lymphoma after tubercular infection. In addition, male gender and old age (>60 years) was associated with the B-cell NHL. Conclusion: A high proportion of Mycobacterium tuberculosis infection was found in patients with lymphoma. In TB-infected patients, older age and male gender are associated with susceptibility to lymphoma, suggesting the awareness of a screening program might be useful for early detection of lymphoma.

CCL2 Chemokine Gene Expression in Lymph Nodes May Have Prognostic Value in Non-Hodgkin’s Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4644-4644
Author(s):  
Grzegorz Mazur ◽  
Ilona Kryczek ◽  
Tomasz Wrobel ◽  
Dorota Dlubek ◽  
Aleksandra Klimczak ◽  
...  
Keyword(s):  
Gene Expression ◽  
T Cell ◽  
Lymph Nodes ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ccl2 Expression ◽  
Hodgkin's Lymphomas

Abstract Background: Non-Hodgkin’s lymphomas (nHL) constitute complex group of lymphoproliferative disorders in which clinical outcome is difficult to predict at the moment of diagnosis. Formation of International Prognostic Index has provided criteria dividing patients into groups of risk, but still new prognostic factors are being searched. There are several reports that some chemokines including CCL2 play a role in progression of solid tumours (bladder, ovarian, non-small cell lung cancer) and increased level of CCL2 has been found in myeloma multiple. CCL2 is the chemokine produced by tumour cells and some stromal cells, such as: fibroblasts, endothelial cells and monocytes. CCL2 is chemoattractant for monocytes, T, NK and dendritic cells and basophlis. CCL2 has also angiogenic activity and is necessary for tumour growth and metastatic process. Aim: The purpose of this study was to evaluate gene expression of CCL2 chemokine in lymphoma and reactive lymph nodes. Material and methods: CCL2 gene expression was determined in 37 lymph nodes of lymphoma patients (26 B-cell lymphoma: 12 females and 14 males aged 26–73 years; 4 T-cell lymphoma: males aged 41–81 years; 7 Hodgkin’s lymphoma: 4 females and 3 males aged 21–58 years) and 25 reactive lymph nodes (15 females, 10 males, aged 18–59 years, median age 32 years). Gene expression was determined by the reverse transcription (RT)-polymerase chain reaction method. Scale of expression was 0–3 AU. Statistical analysis was performed using Kruskall-Wallis and Mann-Witney tests (p&lt;0,05). Results: In lymphoma lymph nodes CCL2 expression was significantly higher (2–3 AU) than in reactive lymph nodes (p=0,0008). Increased CCL2 expression was detected in 19/26 (73%) B-cell lymphoma lymph nodes and all (4/4, 100%) T-cell lymphomas. In reactive lymph nodes 2 AU expression was observed in 7/25 cases (28%). Particularly high expression characterized diffuse large B-cell lymphomas and Burkitt lymphomas. Patients with high CCL2 expression had significantly shorter survival than those with low expression (p=0,004). There was positive correlation between CCL2 expression and Ki-67 proliferation marker (p&lt;0,05; coefficient 0,39). Conclusions: CCL2 expression is higher in B-cell lymphoma lymph nodes than in reactive lymph nodes. Multivariate analysis has proved CCL2 as independent prognostic factor in nHL.

scholarly journals Nodular Lymphocyte Predominant Hodgkin’s Lymphoma with T Cell/ Histiocyte Rich Large B Cell Lymphoma Like Transformation

2020 ◽  
Vol 7 (8) ◽  
pp. C103-106
Author(s):  
Sakshi Batra ◽  
Harsh Batra ◽  
Charanjeet Ahluwalia ◽  
Sunil Ranga
Keyword(s):  
T Cell ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Growth Patterns ◽  
Hodgkin's Lymphoma ◽  
Variant Form ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) is an uncommon variant form of Hodgkin’s lymphoma with a worldwide incidence of 5%. 1 It has long been recognized that NLPHL can have varied growth patterns, including some with diffuse areas and/or numerous T cells.2 NLPHL may evolve to a completely diffuse T-cell–rich proliferation lacking any follicular dendritic cells which would be consistent with a T-cell histiocyte-rich large B-cell lymphoma (THRLBCL) or can be associated with such a proliferation at a separate site. Recent data indicate that progression to a process with features of THRLBCL is associated with a more aggressive clinical course, and requires different management, hence the significance of diagnosing correctly THRLBCL-like transformation of NLPHL. We report a case of THRLBCL-like transformation of NLPHL in an 11-year old male child.

Sign in / Sign up

Export Citation Format

Share Document